Credit score: Pixabay/CC0 Public Area
New analysis to be introduced on the European Congress on Weight problems (ECO 2025, Malaga, Spain, 11–14 Might) exhibits that round two-thirds of individuals of the SURMOUNT-1 trial had solely regained 5% or much less of their so-called nadir (or lowest weight) three years after starting therapy with tirzepatide.
The research is by Professor Louis Aronne, Complete Weight Management Heart, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medication, New York, NY, U.S., and co-authors from Eli Lilly and Firm, Indianapolis, IN, U.S.
Weight problems administration is a long-term journey throughout which fluctuations in physique weight are anticipated to happen. For some sufferers, a earlier nadir weight can grow to be a degree of focus (and disappointment when it can’t be reached once more). Nevertheless, there may be not but clear literature that nadir weight is clinically related. This submit hoc evaluation of the SURMOUNT-1 research, at three years, aimed to evaluate weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide therapy.
The unique SURMOUNT-1 trial was revealed in NEJM in 2022, and located that, throughout 72 weeks, individuals with weight problems handled with 5 mg, 10 mg, or 15 mg of tirzepatide as soon as weekly skilled substantial and sustained reductions in physique weight.
This evaluation included 690 tirzepatide-adherent individuals (65% feminine, 35% male) with a imply age of 49 years, a imply weight of 107 kg, and a imply BMI of 38.6 kg/m2 who have been chosen from the unique SURMOUNT-1 cohort on the idea they’d been treatment-adherent throughout the three years (with 75% or extra of deliberate doses acquired) and have been dwelling with weight problems (a BMI of a minimum of 30 kg/m2), or chubby (a BMI of a minimum of 27 kg/m2) and prediabetes, and had been individuals within the SURMOUNT-1 research and had misplaced a minimum of 5% of their baseline weight when reaching their nadir weight (the bottom weight achieved throughout therapy).
Weight regain from nadir to Week 176 was outlined because the distinction between % weight discount from baseline to nadir and % weight discount from baseline to Week 176. Weight regain analyses have been calculated as a imply throughout teams and have been categorized as lower than 5%, 5% to 10%, and 10% or extra weight regain.
The evaluation confirmed that the imply time to nadir weight was 22 months (96 weeks). The imply % weight discount at nadir weight was 23.1%. The imply % weight regain from nadir weight to Week 176 was 3.7%, that means that throughout the 690 individuals over these three years there was a imply proportion weight discount of 19.4% (23.1% minus 3.7%).
At Week 176, 73%, 19%, and eight% of individuals handled with tirzepatide 5 mg (227 individuals) regained lower than 5%, 5% to 10%, and 10% or extra from nadir weight, respectively. Equally, 65%, 26%, and 9% of individuals handled with tirzepatide 10 mg (N=239) regained lower than 5%, 5% to 10%, and 10% or extra weight from nadir to week 176, respectively.
Amongst individuals handled with tirzepatide 15 mg (N=224), 73%, 20%, and seven% skilled lower than 5%, 5% to 10%, and 10% or extra weight regain from nadir to Week 176, respectively.
The authors haven’t but analyzed if there are any variations in weight achieve between women and men or between older and youthful individuals.
Dr. Aronne concludes, “This evaluation discovered that 70% of individuals handled with tirzepatide had restricted weight regain – that means 5% or much less – after their nadir, or lowest weight. Lower than 10% of individuals regained 10% or extra from their nadir weight.
“Overall, these findings suggest that most participants receiving tirzepatide had a relatively stable weight journey over three years in the SURMOUNT-1 three-year study, and managed to avoid any substantial weight regain.”
Supplied by
European Affiliation for the Research of Weight problems
Quotation:
Three-year research of tirzepatide exhibits that almost all sufferers solely regain 5% or much less from their lowest weight (2025, April 11)
retrieved 11 April 2025
from https://medicalxpress.com/information/2025-04-year-tirzepatide-patients-regain-lowest.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
